NCT01038843

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date: Dec 1, 2009
Primary completion: Jul 1, 2010
Completion date: Aug 1, 2010
First posted: —
Last posted: —
Enrollment: 152
Arms / groups: 4 / —
Source: AACT · pre-existing

Sponsors

Vantia LtdLead sponsor
Emory UniversityOverall official - principal investigator
Bay State Clinical Trials, Inc.Overall official - principal investigator
Hudson Valley Urology, PCOverall official - principal investigator
Alabama Research Center, LLCOverall official - principal investigator
Grove Hill Clinical ResearchOverall official - principal investigator
Rapid Medical Research, Inc.Overall official - principal investigator
Medical & Clinical Research AssociatesOverall official - principal investigator
South Broward Research, LLCOverall official - principal investigator
Accumed Research AssociatesOverall official - principal investigator
South Florida Medical ResearchOverall official - principal investigator
Urology Center of FloridaOverall official - principal investigator
Martin Diagnostic ClinicOverall official - principal investigator
Tower Urology Medical GroupOverall official - principal investigator
Health Texas Research InstituteOverall official - principal investigator
Parkhurst Research OrganizationOverall official - principal investigator
Genova Clinical ResearchOverall official - principal investigator
Urology Associates of North TexasOverall official - principal investigator
Avail Clinical ResearchOverall official - principal investigator

Drugs studied

Indications studied

Nocturia

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.